Literature DB >> 27663956

SGLT2 inhibitors: β blockers for the kidney?

Richard E Gilbert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27663956     DOI： 10.1016/S2213-8587(16)30237-6

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  12 in total

Review 1.  Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.

Authors:  David León Jiménez; David Z I Cherney; Petter Bjornstad; Luis Castilla-Guerra; José Pablo Miramontes González
Journal:  Am J Physiol Renal Physiol       Date:  2018-08-01

Review 2.  Acute Kidney Injury and Progression of Diabetic Kidney Disease.

Authors:  Samuel Mon-Wei Yu; Joseph V Bonventre
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

Review 3.  Sex-related differences in diabetic kidney disease: A review on the mechanisms and potential therapeutic implications.

Authors:  Federica Piani; Isabella Melena; Kalie L Tommerdahl; Natalie Nokoff; Robert G Nelson; Meda E Pavkov; Daniël H van Raalte; David Z Cherney; Richard J Johnson; Kristen J Nadeau; Petter Bjornstad
Journal:  J Diabetes Complications       Date:  2020-12-31       Impact factor: 2.852

4.  Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.

Authors:  Per Lundkvist; Maria J Pereira; Petros Katsogiannos; C David Sjöström; Eva Johnsson; Jan W Eriksson
Journal:  Diabetes Obes Metab       Date:  2017-05-31       Impact factor: 6.577

Review 5.  Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.

Authors:  Motoaki Sano
Journal:  J Clin Med Res       Date:  2017-04-26

6.  Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.

Authors:  Claire C J Dekkers; Sergei Petrykiv; Gozewijn D Laverman; David Z Cherney; Ron T Gansevoort; Hiddo J L Heerspink
Journal:  Diabetes Obes Metab       Date:  2018-04-23       Impact factor: 6.577

7.  Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.

Authors:  Annayya R Aroor; Nitin A Das; Andrea J Carpenter; Javad Habibi; Guanghong Jia; Francisco I Ramirez-Perez; Luis Martinez-Lemus; Camila M Manrique-Acevedo; Melvin R Hayden; Cornel Duta; Ravi Nistala; Eric Mayoux; Jaume Padilla; Bysani Chandrasekar; Vincent G DeMarco
Journal:  Cardiovasc Diabetol       Date:  2018-07-30       Impact factor: 9.951

8.  Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.

Authors:  Hiddo J L Heerspink; Paul Perco; Skander Mulder; Johannes Leierer; Michael K Hansen; Andreas Heinzel; Gert Mayer
Journal:  Diabetologia       Date:  2019-04-17       Impact factor: 10.122

Review 9.  New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.

Authors:  Claire C J Dekkers; Ron T Gansevoort; Hiddo J L Heerspink
Journal:  Curr Diab Rep       Date:  2018-03-27       Impact factor: 4.810

Review 10.  The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition.

Authors:  Muhammad Saad; Umut Gomceli; Pranav Ravi; Andrisael G Lacoste; Neil Shah; Timothy J Vittorio
Journal:  Drugs Context       Date:  2018-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.